ÂÜÀòÂÒÂ×

C. Glenn Begley MBBS (MD-equivalent), PhD, FRACP, FRCPA, FRCPath, FAHMS is a physician and hematologist/medical oncologist, with a PhD in cell and molecular biology.

For 4 years (until March 2021) he served as inaugural CEO of BioCurate, a joint initiative of Monash and Melbourne Universities to achieve impact from their biomedical research.

He served as Chief Scientific Officer at Akriveia Therapeutics (now Xilio), California (2016-2017), and TetraLogic Pharmaceuticals, Pennsylvania (2012-2016), and as non-Executive Director at Oxford BioTherapeutics (2012-2017). He was Vice-President and Global Head of Hematology/Oncology Research at Amgen, Thousand Oaks, California (2002-2012), with responsibility at Amgen’s 5 research sites.